{"id":29131,"date":"2026-10-23T12:15:22","date_gmt":"2026-10-23T16:15:22","guid":{"rendered":"https:\/\/www.cryoport.com\/?p=29131"},"modified":"2026-10-23T12:45:18","modified_gmt":"2026-10-23T16:45:18","slug":"actualites-blog-donner-la-priorite-aux-decisions-de-commercialisation-aux-premieres-etapes-du-developpement-des-therapies-de-pointe","status":"publish","type":"post","link":"https:\/\/www.cryoport.com\/fr\/actualites-blog-donner-la-priorite-aux-decisions-de-commercialisation-aux-premieres-etapes-du-developpement-des-therapies-de-pointe\/","title":{"rendered":"Hi\u00e9rarchiser les d\u00e9cisions de commercialisation d\u00e8s les premi\u00e8res \u00e9tapes du d\u00e9veloppement des th\u00e9rapies innovantes"},"content":{"rendered":"","protected":false},"excerpt":{"rendered":"

Les entreprises biopharmaceutiques performantes commencent \u00e0 \u00e9laborer une strat\u00e9gie de commercialisation d\u00e8s les premi\u00e8res phases de d\u00e9veloppement. Plut\u00f4t que d\u2019attendre que leur th\u00e9rapie innovante ou leur produit biologique approche des phases d\u2019essais pivots, les d\u00e9veloppeurs devraient prendre ces d\u00e9cisions d\u00e8s que possible. <\/p>\n

Dans un entretien r\u00e9cent accord\u00e9 \u00e0 Pharmaceutical Commerce, Gwen Erskine, directrice principale des services de conseil chez Cryoport Systems, explique pourquoi le fait de donner la priorit\u00e9 \u00e0 la pr\u00e9paration \u00e0 la commercialisation d\u00e8s les premi\u00e8res phases de d\u00e9veloppement permet d\u2019optimiser la rentabilit\u00e9, la flexibilit\u00e9 et la gestion des risques.<\/p>\n","protected":false},"author":38,"featured_media":29137,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"single-with-related.php","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[226],"tags":[481],"class_list":["post-29131","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-articles-fr","tag-gestion-de-la-chaine-dapprovisionnement"],"acf":[],"yoast_head":"\nHi\u00e9rarchiser les d\u00e9cisions de commercialisation d\u00e8s les premi\u00e8res \u00e9tapes du d\u00e9veloppement des th\u00e9rapies innovantes - Cryoport Systems<\/title>\n<meta name=\"description\" content=\"Les entreprises biopharmaceutiques performantes commencent \u00e0 \u00e9laborer une strat\u00e9gie de commercialisation d\u00e8s les premi\u00e8res phases de d\u00e9veloppement. Plut\u00f4t que d\u2019attendre que leur th\u00e9rapie innovante ou leur produit biologique approche des phases d\u2019essais pivots, les d\u00e9veloppeurs devraient prendre ces d\u00e9cisions d\u00e8s que possible. Dans un entretien r\u00e9cent accord\u00e9 \u00e0 Pharmaceutical Commerce, Gwen Erskine, directrice principale des services de conseil chez Cryoport Systems, explique pourquoi le fait de donner la priorit\u00e9 \u00e0 la pr\u00e9paration \u00e0 la commercialisation d\u00e8s les premi\u00e8res phases de d\u00e9veloppement permet d\u2019optimiser la rentabilit\u00e9, la flexibilit\u00e9 et la gestion des risques.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.cryoport.com\/fr\/actualites-blog-donner-la-priorite-aux-decisions-de-commercialisation-aux-premieres-etapes-du-developpement-des-therapies-de-pointe\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Hi\u00e9rarchiser les d\u00e9cisions de commercialisation d\u00e8s les premi\u00e8res \u00e9tapes du d\u00e9veloppement des th\u00e9rapies innovantes - Cryoport Systems\" \/>\n<meta property=\"og:description\" content=\"Les entreprises biopharmaceutiques performantes commencent \u00e0 \u00e9laborer une strat\u00e9gie de commercialisation d\u00e8s les premi\u00e8res phases de d\u00e9veloppement. Plut\u00f4t que d\u2019attendre que leur th\u00e9rapie innovante ou leur produit biologique approche des phases d\u2019essais pivots, les d\u00e9veloppeurs devraient prendre ces d\u00e9cisions d\u00e8s que possible. Dans un entretien r\u00e9cent accord\u00e9 \u00e0 Pharmaceutical Commerce, Gwen Erskine, directrice principale des services de conseil chez Cryoport Systems, explique pourquoi le fait de donner la priorit\u00e9 \u00e0 la pr\u00e9paration \u00e0 la commercialisation d\u00e8s les premi\u00e8res phases de d\u00e9veloppement permet d\u2019optimiser la rentabilit\u00e9, la flexibilit\u00e9 et la gestion des risques.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.cryoport.com\/fr\/actualites-blog-donner-la-priorite-aux-decisions-de-commercialisation-aux-premieres-etapes-du-developpement-des-therapies-de-pointe\/\" \/>\n<meta property=\"og:site_name\" content=\"Cryoport Systems\" \/>\n<meta property=\"article:published_time\" content=\"2026-10-23T16:15:22+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-10-23T16:45:18+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.cryoport.com\/wp-content\/uploads\/2026\/10\/Pharm_Commerce_Interview_GwenErskine_BLOG.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"628\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"smendez\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@cryoport\" \/>\n<meta name=\"twitter:site\" content=\"@cryoport\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"smendez\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.cryoport.com\\\/fr\\\/actualites-blog-donner-la-priorite-aux-decisions-de-commercialisation-aux-premieres-etapes-du-developpement-des-therapies-de-pointe\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.cryoport.com\\\/fr\\\/actualites-blog-donner-la-priorite-aux-decisions-de-commercialisation-aux-premieres-etapes-du-developpement-des-therapies-de-pointe\\\/\"},\"author\":{\"name\":\"smendez\",\"@id\":\"https:\\\/\\\/www.cryoport.com\\\/fr\\\/#\\\/schema\\\/person\\\/41e3344a83f354e30051a36b4e0a5f86\"},\"headline\":\"Hi\u00e9rarchiser les d\u00e9cisions de commercialisation d\u00e8s les premi\u00e8res \u00e9tapes du d\u00e9veloppement des th\u00e9rapies innovantes\",\"datePublished\":\"2026-10-23T16:15:22+00:00\",\"dateModified\":\"2026-10-23T16:45:18+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.cryoport.com\\\/fr\\\/actualites-blog-donner-la-priorite-aux-decisions-de-commercialisation-aux-premieres-etapes-du-developpement-des-therapies-de-pointe\\\/\"},\"wordCount\":20,\"publisher\":{\"@id\":\"https:\\\/\\\/www.cryoport.com\\\/fr\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/www.cryoport.com\\\/fr\\\/actualites-blog-donner-la-priorite-aux-decisions-de-commercialisation-aux-premieres-etapes-du-developpement-des-therapies-de-pointe\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.cryoport.com\\\/wp-content\\\/uploads\\\/2026\\\/10\\\/Pharm_Commerce_Interview_GwenErskine_BLOG.png\",\"keywords\":[\"Gestion de la cha\u00eene d'approvisionnement\"],\"articleSection\":[\"Articles\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.cryoport.com\\\/fr\\\/actualites-blog-donner-la-priorite-aux-decisions-de-commercialisation-aux-premieres-etapes-du-developpement-des-therapies-de-pointe\\\/\",\"url\":\"https:\\\/\\\/www.cryoport.com\\\/fr\\\/actualites-blog-donner-la-priorite-aux-decisions-de-commercialisation-aux-premieres-etapes-du-developpement-des-therapies-de-pointe\\\/\",\"name\":\"Hi\u00e9rarchiser les d\u00e9cisions de commercialisation d\u00e8s les premi\u00e8res \u00e9tapes du d\u00e9veloppement des th\u00e9rapies innovantes - Cryoport Systems\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.cryoport.com\\\/fr\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.cryoport.com\\\/fr\\\/actualites-blog-donner-la-priorite-aux-decisions-de-commercialisation-aux-premieres-etapes-du-developpement-des-therapies-de-pointe\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.cryoport.com\\\/fr\\\/actualites-blog-donner-la-priorite-aux-decisions-de-commercialisation-aux-premieres-etapes-du-developpement-des-therapies-de-pointe\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.cryoport.com\\\/wp-content\\\/uploads\\\/2026\\\/10\\\/Pharm_Commerce_Interview_GwenErskine_BLOG.png\",\"datePublished\":\"2026-10-23T16:15:22+00:00\",\"dateModified\":\"2026-10-23T16:45:18+00:00\",\"description\":\"Les entreprises biopharmaceutiques performantes commencent \u00e0 \u00e9laborer une strat\u00e9gie de commercialisation d\u00e8s les premi\u00e8res phases de d\u00e9veloppement. Plut\u00f4t que d\u2019attendre que leur th\u00e9rapie innovante ou leur produit biologique approche des phases d\u2019essais pivots, les d\u00e9veloppeurs devraient prendre ces d\u00e9cisions d\u00e8s que possible. Dans un entretien r\u00e9cent accord\u00e9 \u00e0 Pharmaceutical Commerce, Gwen Erskine, directrice principale des services de conseil chez Cryoport Systems, explique pourquoi le fait de donner la priorit\u00e9 \u00e0 la pr\u00e9paration \u00e0 la commercialisation d\u00e8s les premi\u00e8res phases de d\u00e9veloppement permet d\u2019optimiser la rentabilit\u00e9, la flexibilit\u00e9 et la gestion des risques.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.cryoport.com\\\/fr\\\/actualites-blog-donner-la-priorite-aux-decisions-de-commercialisation-aux-premieres-etapes-du-developpement-des-therapies-de-pointe\\\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.cryoport.com\\\/fr\\\/actualites-blog-donner-la-priorite-aux-decisions-de-commercialisation-aux-premieres-etapes-du-developpement-des-therapies-de-pointe\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/www.cryoport.com\\\/fr\\\/actualites-blog-donner-la-priorite-aux-decisions-de-commercialisation-aux-premieres-etapes-du-developpement-des-therapies-de-pointe\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.cryoport.com\\\/wp-content\\\/uploads\\\/2026\\\/10\\\/Pharm_Commerce_Interview_GwenErskine_BLOG.png\",\"contentUrl\":\"https:\\\/\\\/www.cryoport.com\\\/wp-content\\\/uploads\\\/2026\\\/10\\\/Pharm_Commerce_Interview_GwenErskine_BLOG.png\",\"width\":1200,\"height\":628},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.cryoport.com\\\/fr\\\/actualites-blog-donner-la-priorite-aux-decisions-de-commercialisation-aux-premieres-etapes-du-developpement-des-therapies-de-pointe\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.cryoport.com\\\/fr\\\/homepage\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Hi\u00e9rarchiser les d\u00e9cisions de commercialisation d\u00e8s les premi\u00e8res \u00e9tapes du d\u00e9veloppement des th\u00e9rapies innovantes\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.cryoport.com\\\/fr\\\/#website\",\"url\":\"https:\\\/\\\/www.cryoport.com\\\/fr\\\/\",\"name\":\"Cryoport Systems\",\"description\":\"Enabling the Future of Medicine\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.cryoport.com\\\/fr\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.cryoport.com\\\/fr\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.cryoport.com\\\/fr\\\/#organization\",\"name\":\"Cryoport Systems\",\"url\":\"https:\\\/\\\/www.cryoport.com\\\/fr\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/www.cryoport.com\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.cryoport.com\\\/wp-content\\\/uploads\\\/2023\\\/12\\\/systems-square.png\",\"contentUrl\":\"https:\\\/\\\/www.cryoport.com\\\/wp-content\\\/uploads\\\/2023\\\/12\\\/systems-square.png\",\"width\":1200,\"height\":1200,\"caption\":\"Cryoport Systems\"},\"image\":{\"@id\":\"https:\\\/\\\/www.cryoport.com\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/x.com\\\/cryoport\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/856887\",\"https:\\\/\\\/www.youtube.com\\\/user\\\/CryoportVideo\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.cryoport.com\\\/fr\\\/#\\\/schema\\\/person\\\/41e3344a83f354e30051a36b4e0a5f86\",\"name\":\"smendez\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/3ce9d56659c228959822d42e6e9146f3170fc590e93aa3adda9bb496df111835?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/3ce9d56659c228959822d42e6e9146f3170fc590e93aa3adda9bb496df111835?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/3ce9d56659c228959822d42e6e9146f3170fc590e93aa3adda9bb496df111835?s=96&d=mm&r=g\",\"caption\":\"smendez\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Hi\u00e9rarchiser les d\u00e9cisions de commercialisation d\u00e8s les premi\u00e8res \u00e9tapes du d\u00e9veloppement des th\u00e9rapies innovantes - Cryoport Systems","description":"Les entreprises biopharmaceutiques performantes commencent \u00e0 \u00e9laborer une strat\u00e9gie de commercialisation d\u00e8s les premi\u00e8res phases de d\u00e9veloppement. Plut\u00f4t que d\u2019attendre que leur th\u00e9rapie innovante ou leur produit biologique approche des phases d\u2019essais pivots, les d\u00e9veloppeurs devraient prendre ces d\u00e9cisions d\u00e8s que possible. Dans un entretien r\u00e9cent accord\u00e9 \u00e0 Pharmaceutical Commerce, Gwen Erskine, directrice principale des services de conseil chez Cryoport Systems, explique pourquoi le fait de donner la priorit\u00e9 \u00e0 la pr\u00e9paration \u00e0 la commercialisation d\u00e8s les premi\u00e8res phases de d\u00e9veloppement permet d\u2019optimiser la rentabilit\u00e9, la flexibilit\u00e9 et la gestion des risques.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.cryoport.com\/fr\/actualites-blog-donner-la-priorite-aux-decisions-de-commercialisation-aux-premieres-etapes-du-developpement-des-therapies-de-pointe\/","og_locale":"fr_FR","og_type":"article","og_title":"Hi\u00e9rarchiser les d\u00e9cisions de commercialisation d\u00e8s les premi\u00e8res \u00e9tapes du d\u00e9veloppement des th\u00e9rapies innovantes - Cryoport Systems","og_description":"Les entreprises biopharmaceutiques performantes commencent \u00e0 \u00e9laborer une strat\u00e9gie de commercialisation d\u00e8s les premi\u00e8res phases de d\u00e9veloppement. Plut\u00f4t que d\u2019attendre que leur th\u00e9rapie innovante ou leur produit biologique approche des phases d\u2019essais pivots, les d\u00e9veloppeurs devraient prendre ces d\u00e9cisions d\u00e8s que possible. Dans un entretien r\u00e9cent accord\u00e9 \u00e0 Pharmaceutical Commerce, Gwen Erskine, directrice principale des services de conseil chez Cryoport Systems, explique pourquoi le fait de donner la priorit\u00e9 \u00e0 la pr\u00e9paration \u00e0 la commercialisation d\u00e8s les premi\u00e8res phases de d\u00e9veloppement permet d\u2019optimiser la rentabilit\u00e9, la flexibilit\u00e9 et la gestion des risques.","og_url":"https:\/\/www.cryoport.com\/fr\/actualites-blog-donner-la-priorite-aux-decisions-de-commercialisation-aux-premieres-etapes-du-developpement-des-therapies-de-pointe\/","og_site_name":"Cryoport Systems","article_published_time":"2026-10-23T16:15:22+00:00","article_modified_time":"2026-10-23T16:45:18+00:00","og_image":[{"width":1200,"height":628,"url":"https:\/\/www.cryoport.com\/wp-content\/uploads\/2026\/10\/Pharm_Commerce_Interview_GwenErskine_BLOG.png","type":"image\/png"}],"author":"smendez","twitter_card":"summary_large_image","twitter_creator":"@cryoport","twitter_site":"@cryoport","twitter_misc":{"\u00c9crit par":"smendez"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.cryoport.com\/fr\/actualites-blog-donner-la-priorite-aux-decisions-de-commercialisation-aux-premieres-etapes-du-developpement-des-therapies-de-pointe\/#article","isPartOf":{"@id":"https:\/\/www.cryoport.com\/fr\/actualites-blog-donner-la-priorite-aux-decisions-de-commercialisation-aux-premieres-etapes-du-developpement-des-therapies-de-pointe\/"},"author":{"name":"smendez","@id":"https:\/\/www.cryoport.com\/fr\/#\/schema\/person\/41e3344a83f354e30051a36b4e0a5f86"},"headline":"Hi\u00e9rarchiser les d\u00e9cisions de commercialisation d\u00e8s les premi\u00e8res \u00e9tapes du d\u00e9veloppement des th\u00e9rapies innovantes","datePublished":"2026-10-23T16:15:22+00:00","dateModified":"2026-10-23T16:45:18+00:00","mainEntityOfPage":{"@id":"https:\/\/www.cryoport.com\/fr\/actualites-blog-donner-la-priorite-aux-decisions-de-commercialisation-aux-premieres-etapes-du-developpement-des-therapies-de-pointe\/"},"wordCount":20,"publisher":{"@id":"https:\/\/www.cryoport.com\/fr\/#organization"},"image":{"@id":"https:\/\/www.cryoport.com\/fr\/actualites-blog-donner-la-priorite-aux-decisions-de-commercialisation-aux-premieres-etapes-du-developpement-des-therapies-de-pointe\/#primaryimage"},"thumbnailUrl":"https:\/\/www.cryoport.com\/wp-content\/uploads\/2026\/10\/Pharm_Commerce_Interview_GwenErskine_BLOG.png","keywords":["Gestion de la cha\u00eene d'approvisionnement"],"articleSection":["Articles"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/www.cryoport.com\/fr\/actualites-blog-donner-la-priorite-aux-decisions-de-commercialisation-aux-premieres-etapes-du-developpement-des-therapies-de-pointe\/","url":"https:\/\/www.cryoport.com\/fr\/actualites-blog-donner-la-priorite-aux-decisions-de-commercialisation-aux-premieres-etapes-du-developpement-des-therapies-de-pointe\/","name":"Hi\u00e9rarchiser les d\u00e9cisions de commercialisation d\u00e8s les premi\u00e8res \u00e9tapes du d\u00e9veloppement des th\u00e9rapies innovantes - Cryoport Systems","isPartOf":{"@id":"https:\/\/www.cryoport.com\/fr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.cryoport.com\/fr\/actualites-blog-donner-la-priorite-aux-decisions-de-commercialisation-aux-premieres-etapes-du-developpement-des-therapies-de-pointe\/#primaryimage"},"image":{"@id":"https:\/\/www.cryoport.com\/fr\/actualites-blog-donner-la-priorite-aux-decisions-de-commercialisation-aux-premieres-etapes-du-developpement-des-therapies-de-pointe\/#primaryimage"},"thumbnailUrl":"https:\/\/www.cryoport.com\/wp-content\/uploads\/2026\/10\/Pharm_Commerce_Interview_GwenErskine_BLOG.png","datePublished":"2026-10-23T16:15:22+00:00","dateModified":"2026-10-23T16:45:18+00:00","description":"Les entreprises biopharmaceutiques performantes commencent \u00e0 \u00e9laborer une strat\u00e9gie de commercialisation d\u00e8s les premi\u00e8res phases de d\u00e9veloppement. Plut\u00f4t que d\u2019attendre que leur th\u00e9rapie innovante ou leur produit biologique approche des phases d\u2019essais pivots, les d\u00e9veloppeurs devraient prendre ces d\u00e9cisions d\u00e8s que possible. Dans un entretien r\u00e9cent accord\u00e9 \u00e0 Pharmaceutical Commerce, Gwen Erskine, directrice principale des services de conseil chez Cryoport Systems, explique pourquoi le fait de donner la priorit\u00e9 \u00e0 la pr\u00e9paration \u00e0 la commercialisation d\u00e8s les premi\u00e8res phases de d\u00e9veloppement permet d\u2019optimiser la rentabilit\u00e9, la flexibilit\u00e9 et la gestion des risques.","breadcrumb":{"@id":"https:\/\/www.cryoport.com\/fr\/actualites-blog-donner-la-priorite-aux-decisions-de-commercialisation-aux-premieres-etapes-du-developpement-des-therapies-de-pointe\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.cryoport.com\/fr\/actualites-blog-donner-la-priorite-aux-decisions-de-commercialisation-aux-premieres-etapes-du-developpement-des-therapies-de-pointe\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.cryoport.com\/fr\/actualites-blog-donner-la-priorite-aux-decisions-de-commercialisation-aux-premieres-etapes-du-developpement-des-therapies-de-pointe\/#primaryimage","url":"https:\/\/www.cryoport.com\/wp-content\/uploads\/2026\/10\/Pharm_Commerce_Interview_GwenErskine_BLOG.png","contentUrl":"https:\/\/www.cryoport.com\/wp-content\/uploads\/2026\/10\/Pharm_Commerce_Interview_GwenErskine_BLOG.png","width":1200,"height":628},{"@type":"BreadcrumbList","@id":"https:\/\/www.cryoport.com\/fr\/actualites-blog-donner-la-priorite-aux-decisions-de-commercialisation-aux-premieres-etapes-du-developpement-des-therapies-de-pointe\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.cryoport.com\/fr\/homepage\/"},{"@type":"ListItem","position":2,"name":"Hi\u00e9rarchiser les d\u00e9cisions de commercialisation d\u00e8s les premi\u00e8res \u00e9tapes du d\u00e9veloppement des th\u00e9rapies innovantes"}]},{"@type":"WebSite","@id":"https:\/\/www.cryoport.com\/fr\/#website","url":"https:\/\/www.cryoport.com\/fr\/","name":"Cryoport Systems","description":"Enabling the Future of Medicine","publisher":{"@id":"https:\/\/www.cryoport.com\/fr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.cryoport.com\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/www.cryoport.com\/fr\/#organization","name":"Cryoport Systems","url":"https:\/\/www.cryoport.com\/fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.cryoport.com\/fr\/#\/schema\/logo\/image\/","url":"https:\/\/www.cryoport.com\/wp-content\/uploads\/2023\/12\/systems-square.png","contentUrl":"https:\/\/www.cryoport.com\/wp-content\/uploads\/2023\/12\/systems-square.png","width":1200,"height":1200,"caption":"Cryoport Systems"},"image":{"@id":"https:\/\/www.cryoport.com\/fr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/x.com\/cryoport","https:\/\/www.linkedin.com\/company\/856887","https:\/\/www.youtube.com\/user\/CryoportVideo"]},{"@type":"Person","@id":"https:\/\/www.cryoport.com\/fr\/#\/schema\/person\/41e3344a83f354e30051a36b4e0a5f86","name":"smendez","image":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/secure.gravatar.com\/avatar\/3ce9d56659c228959822d42e6e9146f3170fc590e93aa3adda9bb496df111835?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/3ce9d56659c228959822d42e6e9146f3170fc590e93aa3adda9bb496df111835?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/3ce9d56659c228959822d42e6e9146f3170fc590e93aa3adda9bb496df111835?s=96&d=mm&r=g","caption":"smendez"}}]}},"_links":{"self":[{"href":"https:\/\/www.cryoport.com\/fr\/wp-json\/wp\/v2\/posts\/29131","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.cryoport.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.cryoport.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.cryoport.com\/fr\/wp-json\/wp\/v2\/users\/38"}],"replies":[{"embeddable":true,"href":"https:\/\/www.cryoport.com\/fr\/wp-json\/wp\/v2\/comments?post=29131"}],"version-history":[{"count":2,"href":"https:\/\/www.cryoport.com\/fr\/wp-json\/wp\/v2\/posts\/29131\/revisions"}],"predecessor-version":[{"id":29148,"href":"https:\/\/www.cryoport.com\/fr\/wp-json\/wp\/v2\/posts\/29131\/revisions\/29148"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.cryoport.com\/fr\/wp-json\/wp\/v2\/media\/29137"}],"wp:attachment":[{"href":"https:\/\/www.cryoport.com\/fr\/wp-json\/wp\/v2\/media?parent=29131"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.cryoport.com\/fr\/wp-json\/wp\/v2\/categories?post=29131"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.cryoport.com\/fr\/wp-json\/wp\/v2\/tags?post=29131"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}